Skip to Content

Markets
Technicals
Companies
Earnings
Close-Up
Themes

News

Market and company headlines

CYDYAll

Loading

A personal project for following the US markets. Free, ad-free and open source.

Weekly Recap

Every Sunday morning: the week's earnings behind you and the calendar ahead, in one email.

Get It by Email

Market

Markets
Companies
Stock Screener
Macro
Earnings
Technical Analysis
Calendar
Compare
Thematic Lists
Famous Investors

Reading

Guide
Close-Up
Community
News
Brief Archive
Glossary
Tax Calculator
RSS

Account

Watchlist
My Posts
Bell Report
Portfolio
Settings
Privacy

© 2026 Opening BellPrivacy About What's New ContactNot Investment AdviceAhmet Akyapı

Markets Earnings Close-Up Menu

Nasdaq 100 · QQQ722.18+ 1.40%S&P 500 · SPY769.66+ 0.56%Dow Jones · DIA523.28+ 0.06%Russell 2000 · IWM280.18+ 1.15%

CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026
Phase 2 CLOVER study enrolled 66 patients across seven sites in metastatic colorectal cancerUpdated data show universal CCR5 expression, early ctDNA reductions and favorable tolerability VANCOUVER, Washington, Oct. 26, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including co
Yahoo08:30YesterdayCYDY

16:00-20:00Oct 192 Stories

CytoDyn Highlights Early CLOVER Data, Names Robert Hoffman CEO
CytoDyn (OTCMKTS:CYDY) provided an update on its Phase II CLOVER study of leronlimab in metastatic colorectal cancer, highlighting early circulating tumor DNA, or ctDNA, data, preliminary clinical observations and plans for additional studies. The company also announced that CFO Robert Hoffman will
Yahoo19:02CYDY
CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer
Dr. Jacob Lalezari to remain with Company in scientific innovation and discovery role VANCOUVER, Washington, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple solid-tumor oncology indications, including colorectal cancer (mCRC) and metastatic triple-negative breast cancer (mTNBC), tod
Yahoo16:50CYDY

15:00Oct 191 Story

CytoDyn Inc. (CYDY) Discusses Latest Scientific, Clinical, Operational, and Financial Progress and Upcoming Priorities Transcript
SeekingAlpha15:43CYDY

08:00Oct 151 Story

CytoDyn to Host Investor Webcast
VANCOUVER, Wash., Oct. 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple solid-tumor oncology indications, including colorectal cancer (“mCRC”) and metastatic triple-negative breast cancer (“mTNBC”), today announced it will host an investor webcast on October 19, 2026, at 1 p.m. PT, to pro
Yahoo08:30CYDY

08:00Oct 81 Story

CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026
VANCOUVER, Washington, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple solid-tumor oncology indications, including colorectal cancer (mCRC) and metastatic triple-negative breast cancer (mTNBC), today announced that updated clinical data from its ongoing Phase 2 CLOVER study (Clinica
Yahoo08:30CYDY